Business
LSL PHARMA GROUP ANNOUNCES STRONG FISCAL Q3-24 RESULTS AND $2.4 MILLION DEBT FINANCINGS TO SUPPORT ITS GROWTH INITIATIVES
LSL PHARMA GROUP ANNOUNCES STRONG FISCAL Q3-24 RESULTS AND $2.4 MILLION DEBT FINANCINGS TO SUPPOR...
About this update from Lsl Pharma Group Inc
[{"type":"text","content":"\n\n\n\n LSL PHARMA GROUP ANNOUNCES STRONG FISCAL Q3-24 RESULTS AND $2.4 MILLION DEBT FINANCINGS TO SUPPORT ITS GROWTH INITIATIVES\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n Revenues of\n \n $4.0 million\n \n up 60% over Q3-23\n \n\n Adjusted Gross Profit of\n \n $1.5 million\n \n up 90% over Q3-23\n \n\n Operating Profits of\n \n $0.1 million\n \n compared to\n \n $0.3 million\n \n operating loss in Q3-23\n \n\n Adjusted EBITDA of\n \n $0.5 million\n \n up\n \n $0.4 million\n \n over Q3-23\n \n\n YTD-24 Net loss down 84% compared to last year\n \n\n Raised\n \n $2.4 Million\n \n from debt financings to pursue ongoing growth initiatives\n \n\n Doubled production capacity at Steri-Med Pharma\n \n\n Secured\n \n $1.4 million\n \n on new orders from international clients\n \n\n\n\n\n BOUCHERVILLE, QC\n \n\n ,\n \n\n Nov. 25, 2024\n \n\n /CNW/ -\n \n LSL PHARMA GROUP INC\n \n . (TSXV: LSL) (the \"\n \n Corporation\n \n \" or \"\n \n LSL Pharma\n \n \"), a Canadian integrated pharmaceutical company, today reported its financial and operating results for the three- and nine-month periods ended on\n \n September 30, 2024\n \n .\n \n\n\n\n\n\n\n\n\n \"During Q3-24 we saw our three manufacturing sites contribute to our operating results with Virage Santé contributing its first full quarter to the Group's overall performance. We also completed the ramp up of production at both Steri-Med Pharma and LSL Laboratory with the addition of new equipment and services and are looking forward to starting the installation and validation of our second ointment production line at Steri-Med Pharma early in FY-25,\" commented François Roberge, President and Chief Executive Officer of LSL Pharma. \"The series of financial transactions completed since the end of the second quarter have contributed to strengthen our balance sheet and provide liquidities to continue funding our growth initiatives,\" added Mr. Roberge.\n \n\n Commenting on the Q3-24 and YTD-24 financial results,\n \n Luc Mainville\n \n , Executive Vice-President and Chief Fi...